logo
The hidden dangers of feeding wild animals

The hidden dangers of feeding wild animals

Yahooa day ago
Feeding wild elephants might seem kind or exciting, but a new study warns it can lead to serious harm.
Researchers at the University of California San Diego say that giving food to wild animals -- especially elephants -- can change their behavior in dangerous ways.
"Many people, especially foreign tourists, think Asian elephants are tame and docile, like domestic pets," lead author Shermin de Silva, a conservation scientist and professor of biological sciences, said in a UCSD news release.
"They don't realize these are formidable wild animals and try to get too close in order to take photographs or selfies, which can end badly for both parties," she added.
The study, published in the journal Ecological Solutions and Evidence, looked at 18 years of data from elephant tourism areas in Sri Lanka and India.
In Sri Lanka's Udawalawe National Park, researchers found that dozens of elephants had learned to "beg" for food near fences and tourist vehicles.
One male elephant, nicknamed Rambo, became a local celebrity for this behavior.
The impact? Tragic.
Several people were killed or injured in elephant encounters, the news release said.
At least three elephants were killed, and some animals ate plastic bags or other waste while trying to get food.
In India's Sigur region, researchers tracked 11 male elephants who were fed by people. Four of animals later died, likely because of humans.
"Food-conditioned animals can become dangerous, resulting in the injury and death of wildlife, people or both," the researchers wrote.
"These negative impacts counteract potential benefits," they added.
Feeding wild elephants may cause them to lose their natural foraging skills, especially if they start relying on sugary snacks or processed food, researchers said.
It may also raise the risk of disease spreading between people and animals.
While most tourists mean well, experts say the best thing to do is never feed wild animals, no matter how safe it seems.
Feeding animals might feel like helping a friend, the researchers explained.
"But this encourages wild animals to seek food from people, attracting them to areas that can put themselves or people at risk," de Silva said.
"It can be a conduit for disease transfer between species," she said. "Such feeding can also cause animals to lose their ability to forage for themselves if the behavior becomes prevalent, especially with young animals."
More information
The U.S. Fish and Wildlife Service has more on the potential harm in feeding wildlife.
Copyright © 2025 HealthDay. All rights reserved.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why China's $167 Billion Mega-Dam Project In Tibet Is So Controversial
Why China's $167 Billion Mega-Dam Project In Tibet Is So Controversial

Bloomberg

time2 hours ago

  • Bloomberg

Why China's $167 Billion Mega-Dam Project In Tibet Is So Controversial

China has started construction of the world's biggest hydroelectric dam, a project that's set to be far larger than the Three Gorges Dam — already the world's biggest single source of green power — and more expensive than the International Space Station. The colossal undertaking in the mountainous region of Tibet is set to cost around 1.2 trillion yuan ($167 billion), could take at least a decade to complete and would boost China's output of clean energy. It will also stir controversy over the potential impact on the local environment, and could further strain relations with its downstream neighbor, India.

Hong Kong's Bowtie Life Insurance raises $70m in Series C round
Hong Kong's Bowtie Life Insurance raises $70m in Series C round

Yahoo

time2 hours ago

  • Yahoo

Hong Kong's Bowtie Life Insurance raises $70m in Series C round

Hong Kong-based Bowtie Life Insurance Company has secured $70m (HK$549.49m) in its Series C funding round led by Sun Life Hong Kong. The virtual insurer reported annual recurring revenue (ARR) of $80m on a year-over-year basis, Bowtie said. In a LinkedIn post, the company insurer said it registered more than 100% growth year-over-year, exceeding $80m in ARR, and aims to reach $100m by the end of the year. The insurer plans to use the funding to support its growth in the medical insurance sector and expand its preventive healthcare services. Bowtie co-founder and CEO Michael Chan said: 'Sun Life's continued partnership reinforces Bowtie's position as a mission-driven insurer, leveraging technology to better serve customers through simple and transparent products in a friendly digital setting. 'Going forward, Bowtie will continue to benefit from Sun Life's strong capital base and shared purpose of helping clients achieve lifetime financial security and live healthier lives.' Since its establishment in 2018, Sun Life has been investing in all the funding rounds of Bowtie, increasing its equity stake. Bowtie will continue operations under the existing leadership team and remain an associated company of Sun Life with its own brand identity. Sun Life Hong Kong CEO Clement Lam stated: 'Sun Life has been a long-term, committed partner to Bowtie for almost seven years. We are very pleased to strengthen this partnership to support the next phase of growth. 'Through our collaboration with Bowtie, we are combining cutting edge technology with deep insurance expertise, to set standards in delivering meaningful and innovative transformation within the Hong Kong health insurance industry.' To date, Bowtie has secured more than HK$1bn in funding from investors including Sun Life Financial and Mitsui & Co. "Hong Kong's Bowtie Life Insurance raises $70m in Series C round " was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

India In Vitro Diagnostics (IVD) Industry Analysis & Forecast (2025-2034) Featuring Roche, Transasia Bio-Medicals, Bio-Rad Labs, BioMerieux, Sysmex, Abbott, Thermo Fisher Scientific, QIAGEN, Quidel, Danaher
India In Vitro Diagnostics (IVD) Industry Analysis & Forecast (2025-2034) Featuring Roche, Transasia Bio-Medicals, Bio-Rad Labs, BioMerieux, Sysmex, Abbott, Thermo Fisher Scientific, QIAGEN, Quidel, Danaher

Yahoo

time3 hours ago

  • Yahoo

India In Vitro Diagnostics (IVD) Industry Analysis & Forecast (2025-2034) Featuring Roche, Transasia Bio-Medicals, Bio-Rad Labs, BioMerieux, Sysmex, Abbott, Thermo Fisher Scientific, QIAGEN, Quidel, Danaher

The market's 6.10% CAGR reflects advances in molecular diagnostics, healthcare infrastructure expansion, and personalized medicine. Key trends include companies like Sysmex enhancing local operations and WHO expanding diabetes-related IVDs. Abbott, Qiagen, Quidel, and Danaher lead the market's innovation-driven growth. Dublin, July 21, 2025 (GLOBE NEWSWIRE) -- The "India In Vitro Diagnostics Market Report and Forecast 2025-2034" has been added to offering. The India in vitro diagnostics (IVD) market, valued at USD 2.64 billion in 2024, is foreseen to grow at a CAGR of 6.10% from 2025 to 2034, potentially reaching USD 4.77 billion by the end of the period. This growth is primarily driven by the rising prevalence of chronic diseases, government initiatives, technological advancements, and the integration of personalized medicine into healthcare systems. This report answers pivotal questions about market valuation, growth forecasts, key demand drivers, current trends, segment leadership, technology and application dominance, and challenges. It also explores key players' strategies and the impact of strategic partnerships and mergers on market dynamics. Market Overview The IVD sector in India plays a crucial role in preventive healthcare, disease management, and personalized medicine. Driven by increased healthcare awareness and technological advancements in diagnostic technologies, the market is set for significant expansion. Government efforts to enhance healthcare infrastructure and focus on early, precise diagnostics are further powering its growth. Growth Drivers The surge in chronic and non-communicable diseases (NCDs) forms a fundamental growth driver for the IVD market in India. These conditions demand early and accurate diagnosis, thereby elevating the demand for cutting-edge diagnostic technologies. According to India's Ministry of Science and Technology, NCDs account for a substantial portion of mortality and disability, necessitating improved diagnostic solutions. Market Trends Several trends are shaping the market, including the localization of operations by IVD companies and the development of disease-specific IVD solutions. For instance, Sysmex India's commitment to establishing local manufacturing facilities marks a shift towards direct operations, which enhances product availability and customer support. Additionally, the expanding scope of disease-specific diagnostics, such as the WHO's inclusion of diabetes-related tests in its prequalification scope, underscores the market's evolution towards targeted healthcare solutions. Market Segmentation The market is segmented based on products and services (reagents and kits, instruments, software and services), technology (immunodiagnostics, molecular diagnostics, clinical chemistry, among others), application (infectious diseases, diabetes, oncology, and more), end user (hospitals, diagnostic centers, point-of-care testing, etc.), and regions (Northern and Central, Southern, Eastern, Western). Reagents and Kits Segment Dominance The reagents and kits segment leads due to their fundamental role in diagnostic testing. Innovations like Cipla Limited's RT-Direct multiplex COVID-19 RT-PCR test kit highlight the segment's importance, driven by advancements in point-of-care testing technologies and the growing prevalence of chronic and infectious diseases. Key Players Major companies influencing the India IVD market include Abbott, known for its innovative molecular diagnostics; Qiagen, enhancing laboratory efficiency with upcoming automated instruments; Quidel Corporation, offering specialized immunoassays; and Danaher Corporation, addressing chronic disease challenges through advanced diagnostics. Other notable players are F. Hoffmann-La Roche Ltd, Transasia Bio-Medicals Ltd, Bio-Rad Laboratories, Inc., bioMerieux SA, Thermo Fisher Scientific Inc., and Sysmex Corporation. Key Attributes Report Attribute Details No. of Pages 250 Forecast Period 2025-2034 Estimated Market Value (USD) in 2025 $2.64 Billion Forecasted Market Value (USD) by 2034 $4.77 Billion Compound Annual Growth Rate 6.1% Regions Covered India Key Topics Covered Preface Objectives of the Study Key Assumptions Report Coverage - Key Segmentation and Scope Research Methodology Executive Summary In Vitro Diagnostics Market Overview Asia Pacific In Vitro Diagnostics Market Overview India In Vitro Diagnostics Market Overview Vendor Positioning Analysis Key Vendors Prospective Leaders Niche Leaders Disruptors India In Vitro Diagnostics Market Landscape India In Vitro Diagnostics Market: Developers Landscape India In Vitro Diagnostics Market: Product Landscape India In Vitro Diagnostics Market Dynamics Market Drivers and Constraints SWOT Analysis PESTEL Analysis Porter's Five Forces Model Key Demand Indicators Key Price Indicators Industry Events, Initiatives, and Trends Value Chain Analysis India In Vitro Diagnostics Market Segmentation (2018-2034) India In Vitro Diagnostics Market by Product & Services India In Vitro Diagnostics Market by Technology India In Vitro Diagnostics Market by Application India In Vitro Diagnostics Market by End User India In Vitro Diagnostics Market by Region Regulatory Framework Funding and Investment Analysis Analysis by Funding Instances Analysis by Type of Funding Analysis by Funding Amount Analysis by Leading Players Analysis by Leading Investors Analysis by Geography Strategic Initiatives Analysis by Partnership Instances Analysis by Type of Initiatives Analysis by Joint Ventures Analysis by Leading Players Analysis by Geography Supplier Landscape Market Share Analysis (Top 5 Companies) F. Hoffmann-La Roche Ltd. Transasia Bio-Medicals Ltd. Bio-Rad Laboratories, Inc. BioMerieux SA Sysmex Corporation Abbott Thermo Fisher Scientific Inc. QIAGEN Quidel Corporation Danaher Corporation India In Vitro Diagnostics Market - Distribution Model (Additional Insight) Overview Potential Distributors Key Parameters for Distribution Partner Assessment Key Opinion Leaders (KOL) Insights (Additional Insight) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store